These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18565522)

  • 1. Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Mendieta-Azcona C; Alvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2009 Jun; 91(6):2527-36. PubMed ID: 18565522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
    Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
    Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
    Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
    Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
    Carlioglu A; Kaygusuz I; Karakurt F; Gumus II; Uysal A; Kasapoglu B; Armutcu F; Uysal S; Keskin EA; Koca C
    Arch Gynecol Obstet; 2014 Nov; 290(5):929-35. PubMed ID: 24840107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
    Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
    Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
    Kuek S; Wang WJ; Gui SQ
    Zhong Xi Yi Jie He Xue Bao; 2011 Sep; 9(9):965-72. PubMed ID: 21906521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review.
    Jing Z; Liang-Zhi X; Tai-Xiang W; Ying T; Yu-Jian J
    Gynecol Endocrinol; 2008 Oct; 24(10):590-600. PubMed ID: 19012104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
    Ruan X; Song J; Gu M; Wang L; Wang H; Mueck AO
    Arch Gynecol Obstet; 2018 Jun; 297(6):1557-1563. PubMed ID: 29602978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome.
    Mhao NS; Al-Hilli AS; Hadi NR; Jamil DA; Al-Aubaidy HA
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S95-8. PubMed ID: 26703220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
    Kaya MG; Yildirim S; Calapkorur B; Akpek M; Unluhizarci K; Kelestimur F
    Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
    Sahu A; Tripathy P; Mohanty J; Nagy A
    J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin.
    Cui N; Feng X; Zhao Z; Zhang J; Xu Y; Wang L; Hao G
    Clin Ther; 2017 Apr; 39(4):751-758. PubMed ID: 28291580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.